Drug Type Small molecule drug |
Synonyms Sotrastaurin (USAN/INN), Sotrastaurin acetate, AEB 071 + [3] |
Target |
Mechanism PKC inhibitors(Protein kinase C inhibitors), Immunosuppressants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H22N6O2 |
InChIKeyOAVGBZOFDPFGPJ-UHFFFAOYSA-N |
CAS Registry425637-18-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Prolymphocytic Leukemia | Phase 2 | - | 12 Mar 2015 | |
Chronic lymphocytic leukaemia refractory | Phase 2 | - | 12 Mar 2015 | |
Mantle cell lymphoma recurrent | Phase 2 | - | 12 Mar 2015 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | - | 12 Mar 2015 | |
Rhabdoid Tumor of the CNS | Phase 2 | - | 12 Mar 2015 | |
Richter's syndrome | Phase 2 | - | 12 Mar 2015 | |
Small Lymphocytic Lymphoma | Phase 2 | - | 12 Mar 2015 | |
Uveal Melanoma | Phase 2 | US | 01 Aug 2013 | |
Uveal Melanoma | Phase 2 | FR | 01 Aug 2013 | |
Uveal Melanoma | Phase 2 | DE | 01 Aug 2013 |
Phase 1 | 118 | dhgbsanity(jthnstcfpt) = pizntioczu jsshfxbnzg (snxeamleko ) | - | 20 May 2014 | |||
Phase 2 | - | 298 | qsqtvcauki(zubnfzqjrf) = hysztnpfyo wzkthybywc (avddazdnef ) View more | - | 01 Jul 2013 | ||
qsqtvcauki(zubnfzqjrf) = nmxqmwquaf wzkthybywc (avddazdnef ) View more | |||||||
Phase 2 | 124 | Tacrolimus | kkxqixldxv(ckvewenwrx) = The most common adverse events were gastrointestinal disorders (control: 63.6%; sotrastaurin: 88.9%) which led to study-medication discontinuation in two sotrastaurin patients moreviktmc (tbiogpyiwp ) | - | 01 Jul 2011 | ||